Literature DB >> 32630186

Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era?

Ina Valeria Zurlo1, Michele Basso2, Antonia Strippoli2, Maria Alessandra Calegari1,2, Armando Orlandi2, Alessandra Cassano1,2, Mariantonietta Di Salvatore2, Giovanna Garufi1, Emilio Bria1,2, Giampaolo Tortora1,2, Carlo Barone1,2, Carmelo Pozzo2.   

Abstract

Background: Guidelines recommend a perioperative approach in patients with stage II/III gastric cancer, but in real-life many patients receive immediate surgery followed by adjuvant chemotherapy (aCT). Although histologic subtypes may have different response to CT, no study has explored the influence of histotype on the efficacy of perioperative CT (pCT) or aCT. Materials and methods: The objective of the study was to evaluate the impact of clinicopathological features and histology (intestinal or diffuse) on survival according to strategy (pCT vs. aCT). The primary endpoint was overall survival (OS) and the secondary endpoint was event-free survival (EFS).
Results: Out of 203 patients affected by LAGC, 83 received pCT and 120 aCT. At multivariate, histology and LVI in pCT cohort and positive resection margin in the aCT influenced both OS and EFS. No difference in EFS and OS was observed in relation to strategy. However, in the intestinal-type of pCT cohort survival outcomes were significantly higher compared to the aCT cohort, whereas in the diffuse-type were significantly worse in patients receiving pCT compared to those receiving aCT. Conclusions: Although retrospective and small-sized, this study suggests that the benefit of pCT might be limited to the intestinal-type. This hypothesis needs to be confirmed in prospective series.

Entities:  

Keywords:  adjuvant therapy; diffuse histology; gastric cancer; intestinal histology; neo-adjuvant therapy; perioperative therapy

Year:  2020        PMID: 32630186     DOI: 10.3390/cancers12071749

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

Review 1.  Significant position of C-myc in colorectal cancer: a promising therapeutic target.

Authors:  Li Tan; Dong Peng; Yong Cheng
Journal:  Clin Transl Oncol       Date:  2022-08-16       Impact factor: 3.340

2.  Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Where we Stand; An Italian Single Center Perspective.

Authors:  Elisabetta Marino; Luigina Graziosi; Annibale Donini
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

3.  The Value of Whole-Tumor Histogram and Texture Analysis Using Intravoxel Incoherent Motion in Differentiating Pathologic Subtypes of Locally Advanced Gastric Cancer.

Authors:  Huan-Huan Li; Bo Sun; Cong Tan; Rong Li; Cai-Xia Fu; Robert Grimm; Hui Zhu; Wei-Jun Peng
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

4.  Association of serum Interleukin-8 level with lymph node metastasis and tumor recurrence in gastric cancer.

Authors:  Xiang Li; Guiping Xie; Jing Zhai; Yani He; Tongya Wang; Yaohui Wang; Lizong Shen
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

Review 5.  Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Authors:  Cristina Díaz Del Arco; Luis Ortega Medina; Lourdes Estrada Muñoz; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Histol Histopathol       Date:  2021-02-10       Impact factor: 2.303

6.  Prediction of Sensitivity and Efficacy of Clinical Chemotherapy Using Larval Zebrafish Patient-Derived Xenografts of Gastric Cancer.

Authors:  Jing Zhai; Jiaqi Wu; Yaohui Wang; Ruoyue Fan; Guiping Xie; Fangfang Wu; Yani He; Sitong Qian; Aimin Tan; Xuequan Yao; Mingfang He; Lizong Shen
Journal:  Front Cell Dev Biol       Date:  2021-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.